A precision therapy against cancers driven by KIT/PDGFRA mutations.

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Targeting oncogenic kinase drivers with small-molecule inhibitors offers therapeutic benefits in genomically defined cancer populations.
• Heterogeneous kinase mutations can activate cancer pathways through various mechanisms, necessitating tailored drug development.
• Understanding specific disease-driving mutations is crucial for optimizing patient treatment with selective drugs.

Purpose of the Study:

• To present the rationale and preclinical/clinical evaluation of BLU-285, a novel inhibitor targeting oncogenic KIT and PDGFRA alterations.
• To highlight BLU-285's potential in treating cancers with activation loop mutants of KIT and PDGFRA, which are often resistant to current therapies.

Main Methods:

• BLU-285 was designed to selectively inhibit the active conformation of KIT and PDGFRA.
• In vitro and in vivo preclinical models were used to assess the inhibition of various KIT mutants, including activation loop mutants.
• A Phase 1 clinical study evaluated the early safety and activity of BLU-285 in patients with relevant mutations.

Main Results:

• BLU-285 demonstrated potent inhibition of KIT D816V and PDGFRA D842V activation loop mutants with subnanomolar potency.
• The inhibitor effectively targeted other disease-driving KIT mutants in preclinical settings.
• Phase 1 clinical evaluation showed marked activity in patients with aggressive systemic mastocytosis and gastrointestinal stromal tumors harboring KIT or PDGFRA activation loop mutations.

Conclusions:

• BLU-285 is a potent inhibitor of oncogenic KIT and PDGFRA, including key activation loop mutants.
• The drug exhibits promising activity in early clinical studies for specific hematologic and solid tumors.
• BLU-285 represents a targeted therapeutic strategy for patients with cancers driven by KIT and PDGFRA alterations.